

PubMed

National Library of Medicine NLM

PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search PubMed for NS3 and NS4a and protease and inhibitor and Preview Go Clear

Limits Preview/Index **History** Clipboard Details

About Entrez

Text Version

- Search History will be lost after one hour of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.

Search	Most Recent Queries	Time	Result
#4	Search **NS3 and NS4a and protease and inhibitor and peptide**	05:58:23	10
#3	Search **NS3 and NS4a and protease and inhibitor and composition**	05:58:18	0
#2	Search **NS3 and NS4a and protease and inhibitor and pharmaceutical**	05:58:12	0
#1	Search **NS3 and NS4a and protease and inhibitor**	05:57:55	13

Clear History

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Browser
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Mar 17 2003 10:44:01

PubMed

National Library of Medicine

PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search PubMed for NS3 and NS4a and protease and inhibitor Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Display Summary Show: 20 Sort Send to Text

One page.

Items 1-13 of 13

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Browser
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

☐ **1:** Sperandio D, Gangloff AR, Litvak J, Goldsmith R, Hataye JM, Wang VR, Shelton EJ, Elrod K, Janc JW, Clark JM, Rice K, Weinheimer S, Yeung KS, Meanwell NA, Hernandez D, Staab AJ, Venables BL, Spencer JR. Related Articles, Links

Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease.
Bioorg Med Chem Lett. 2002 Nov 4;12(21):3129-33.
PMID: 12372517 [PubMed - indexed for MEDLINE]

☐ **2:** Bianchi E, Pessi A. Related Articles, Links

Inhibiting viral proteases: challenges and opportunities.
Biopolymers. 2002;66(2):101-14. Review.
PMID: 12325160 [PubMed - indexed for MEDLINE]

☐ **3:** Bukhtiyarova M, Rizzo CJ, Kettner CA, Korant BD, Scarnati HT, King RW. Related Articles, Links

Inhibition of the bovine viral diarrhoea virus NS3 serine protease by a boron-modified peptidyl mimetic of its natural substrate.
Antivir Chem Chemother. 2001 Nov;12(6):367-73.
PMID: 12018682 [PubMed - indexed for MEDLINE]

☐ **4:** Ingallinella P, Fattori D, Altamura S, Steinkuhler C, Koch U, Cicero D, Bazzo R, Cortese R, Bianchi E, Pessi A. Related Articles, Links

Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus.
Biochemistry. 2002 Apr 30;41(17):5483-92.
PMID: 11969409 [PubMed - indexed for MEDLINE]

☐ **5:** Archer SJ, Camac DM, Wu ZJ, Farrow NA, Domaille PJ, Wasserman ZR, Bukhtiyarova M, Rizzo C, Jagannathan S, Mersinger LJ, Kettner CA. Related Articles, Links

Hepatitis C virus NS3 protease requires its NS4A cofactor peptide for optimal binding of a boronic acid inhibitor as shown by NMR.
Chem Biol. 2002 Jan;9(1):79-92.
PMID: 11841941 [PubMed - indexed for MEDLINE]

☐ **6:** Fukuda K, Vishnuvardhan D, Sekiya S, Hwang J, Kakiuchi N, Taira K, Shimotohno K, Kumar PK, Nishikawa S. Related Articles, Links

Isolation and characterization of RNA aptamers specific for the hepatitis C virus nonstructural protein 3 protease.
Eur J Biochem. 2000 Jun;267(12):3685-94.
PMID: 10848986 [PubMed - indexed for MEDLINE]

☐ **7:** Fattori D, Urbani A, Brunetti M, Ingenito R, Pessi A, Prendergast K, Narjes F, Matassa VG, De Francesco R, Steinkuhler C. Related Articles, Links

Probing the active site of the hepatitis C virus serine protease by fluorescence resonance energy transfer.
J Biol Chem. 2000 May 19;275(20):15106-13.
PMID: 10809747 [PubMed - indexed for MEDLINE]

☐ **8:** Di Marco S, Rizzi M, Volpari C, Walsh MA, Narjes F, Colarusso S, De Francesco R, Matassa VG, Sollazzo M. Related Articles, Links

Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two

protease-inhibitor complexes.
J Biol Chem. 2000 Mar 10;275(10):7152-7.
PMID: 10702283 [PubMed - indexed for MEDLINE]

☐ **9:** Bianchi E, Orru S, Dal Piaz F, Ingenito R, Casbarra A, Biasiol G, Koch U, Pucci P, Pessi A. Related Articles, Links

Conformational changes in human hepatitis C virus NS3 protease upon binding of product-based inhibitors.
Biochemistry. 1999 Oct 19;38(42):13844-52.
PMID: 10529230 [PubMed - indexed for MEDLINE]

☐ **10:** Chang YS, Liao CL, Tsao CH, Chen MC, Liu CI, Chen LK, Lin YL. Related Articles, Links

Membrane permeabilization by small hydrophobic nonstructural proteins of Japanese encephalitis virus.
J Virol. 1999 Aug;73(8):6257-64.
PMID: 10400716 [PubMed - indexed for MEDLINE]

☐ **11:** Dimasi N, Pasquo A, Martin F, Di Marco S, Steinkuhler C, Cortese R, Sollazzo M. Related Articles, Links

Engineering, characterization and phage display of hepatitis C virus NS3 protease and NS4A cofactor peptide as a single-chain protein.
Protein Eng. 1998 Dec;11(12):1257-65.
PMID: 9930676 [PubMed - indexed for MEDLINE]

☐ **12:** Llinas-Brunet M, Bailey M, Fazal G, Goulet S, Halmos T, Laplante S, Maurice R, Poirier M, Poupart MA, Thibeault D, Wernic D, Lamarre D. Related Articles, Links

Peptide-based inhibitors of the hepatitis C virus serine protease.
Bioorg Med Chem Lett. 1998 Jul 7;8(13):1713-8.
PMID: 9873421 [PubMed - indexed for MEDLINE]

☐ **13:** Landro JA, Raybuck SA, Luong YP, O'Malley ET, Harbeson SL, Morgenstern KA, Rao G, Livingston DJ. Related Articles, Links

Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping.
Biochemistry. 1997 Aug 5;36(31):9340-8.
PMID: 9235976 [PubMed - indexed for MEDLINE]

Display Summary Show: 20 Sort Send to Text

Items 1-13 of 13

One page.

PubMed

National Library of Medicine NLM

Items 1-10 of 10

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Browser
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

☐ **1:** Sperandio D, Gangloff AR, Litvak J, Goldsmith R, Hataye JM, Wang VR, Shelton EJ, Elrod K, Janc JW, Clark JM, Rice K, Weinheimer S, Yeung KS, Meanwell NA, Hernandez D, Staab AJ, Venables BL, Spencer JR. Related Articles, Links

Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease.
Bioorg Med Chem Lett. 2002 Nov 4;12(21):3129-33.
PMID: 12372517 [PubMed - indexed for MEDLINE]

☐ **2:** Bianchi E, Pessi A. Related Articles, Links

Inhibiting viral proteases: challenges and opportunities.
Biopolymers. 2002;66(2):101-14. Review.
PMID: 12325160 [PubMed - indexed for MEDLINE]

☐ **3:** Bukhtiyarova M, Rizzo CJ, Kettner CA, Korant BD, Scarnati HT, King RW. Related Articles, Links

Inhibition of the bovine viral diarrhoea virus NS3 serine protease by a boron-modified peptidyl mimetic of its natural substrate.
Antivir Chem Chemother. 2001 Nov;12(6):367-73.
PMID: 12018682 [PubMed - indexed for MEDLINE]

☐ **4:** Ingallinella P, Fattori D, Altamura S, Steinkuhler C, Koch U, Cicero D, Bazzo R, Cortese R, Bianchi E, Pessi A. Related Articles, Links

Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus.
Biochemistry. 2002 Apr 30;41(17):5483-92.
PMID: 11969409 [PubMed - indexed for MEDLINE]

☐ **5:** Archer SJ, Camac DM, Wu ZJ, Farrow NA, Domaille PJ, Wasserman ZR, Bukhtiyarova M, Rizzo C, Jagannathan S, Mersinger LJ, Kettner CA. Related Articles, Links

Hepatitis C virus NS3 protease requires its NS4A cofactor peptide for optimal binding of a boronic acid inhibitor as shown by NMR.
Chem Biol. 2002 Jan;9(1):79-92.
PMID: 11841941 [PubMed - indexed for MEDLINE]

☐ **6:** Fukuda K, Vishnuvardhan D, Sekiya S, Hwang J, Kakiuchi N, Taira K, Shimotohno K, Kumar PK, Nishikawa S. Related Articles, Links

Isolation and characterization of RNA aptamers specific for the hepatitis C virus nonstructural protein 3 protease.
Eur J Biochem. 2000 Jun;267(12):3685-94.
PMID: 10848986 [PubMed - indexed for MEDLINE]

☐ **7:** Fattori D, Urbani A, Brunetti M, Ingenito R, Pessi A, Prendergast K, Narjes F, Matassa VG, De Francesco R, Steinkuhler C. Related Articles, Links

Probing the active site of the hepatitis C virus serine protease by fluorescence resonance energy transfer.
J Biol Chem. 2000 May 19;275(20):15106-13.
PMID: 10809747 [PubMed - indexed for MEDLINE]

☐ **8:** Dimasi N, Pasquo A, Martin F, Di Marco S, Steinkuhler C, Cortese R, Sollazzo M. Related Articles, Links

Engineering, characterization and phage display of hepatitis C virus NS3 protease and NS4A cofactor peptide as a single-chain protein.

Protein Eng. 1998 Dec;11(12):1257-65.
PMID: 9930676 [PubMed - indexed for MEDLINE]

☐ **9:** Llinas-Brunet M, Bailey M, Fazal G, Goulet S, Halmos T, Laplante S, Maurice R, Poirier M, Poupart MA, Thibeault D, Wernic D, Lamarre D. Related Articles, Links

Peptide-based inhibitors of the hepatitis C virus serine protease.
Bioorg Med Chem Lett. 1998 Jul 7;8(13):1713-8.
PMID: 9873421 [PubMed - indexed for MEDLINE]

☐ **10:** Landro JA, Raybuck SA, Luong YP, O'Malley ET, Harbeson SL, Morgenstern KA, Rao G, Livingston DJ. Related Articles, Links

Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping.
Biochemistry. 1997 Aug 5;36(31):9340-8.
PMID: 9235976 [PubMed - indexed for MEDLINE]

Display Summary Show: 20 Sort Send to Text

Items 1-10 of 10

One page.

Mar 17 2003 10:44:01

1: Bioorg Med Chem Lett 1998 Jul 7;8(13):1713-8

Related Articles, Links

Peptide-based inhibitors of the hepatitis C virus serine protease.

Llinas-Brunet M, Bailey M, Fazal G, Goulet S, Halmos T, Laplante S, Maurice R, Poirier M, Poupart MA, Thibeault D, Wernic D, Lamarre D.

Bio-Mega Research Division, Boehringer Ingelheim (Canada) Ltd., Laval, Quebec, Canada.

Hexapeptide DDIVPC-OH is a competitive inhibitor of the hepatitis C virus (HCV) NS3 protease complexed with NS4A cofactor peptide. This hexapeptide corresponds to the N-terminal cleavage product of an HCV dodecapeptide substrate derived from the NS5A/5B cleavage site. Structure-activity studies on Ac-DDIVPC-OH revealed that side chains of the P4, P3 and P1 residues contribute the most to binding and that the introduction of a D-amino acid at the P5 position improves potency considerably. Furthermore, there is a strong preference for cysteine at the P1 position and conservative replacements, such as serine, are not well tolerated.

PMID: 9873421 [PubMed - indexed for MEDLINE]

Set	Items	Description
S1	428	AU=(SAKSENA A? OR SAKSENA, A?)
S2	576	AU=(GIRIJAVALLABHAN V? OR GIRIJAVALLABHAN, V?)
S3	164	AU=(LOVEY R? OR LOVEY, R?)
S4	53	AU=(JAO E? OR JAO, E?)
S5	2118	AU=(BENNETT F? OR BENNETT, F?)
S6	5255	AU=(MCCORMICK J? OR MCCORMICK, J?)
S7	63247	AU=(WANG H? OR WANG, H?)
S8	1848	AU=(PIKE R? OR PIKE, R?)
S9	210	AU=(BOGEN S? OR BOGEN, S?)
S10	65184	AU=(LIU Y? OR LIU, Y?)
S11	49	AU=(ARASAPPAN A? OR ARASAPPAN, A?)
S12	116	AU=(PAREKH T? OR PAREKH, T?)
S13	1429	AU=(PINTO P? OR PINTO, P?)
S14	187	AU=(NJOROGE F? OR NJOROGE, F)
S15	2945	AU=(GANGULY A? OR GANGULY, A?)
S16	226	AU=(BRUNCK T? OR BRUNCK, T?)
S17	1680	AU=(KEMP S? OR KEMP, S?)
S18	617	AU=(LEVY O? OR LEVY, O?)
S19	55	AU=(LIM-WILBY M? OR LIM-WILBY, M?)
S20	144304	S1:S19
S21	229	S20 AND HCV
S22	70	S20 AND NS3
S23	0	S20 AND HCV AND NS3 (W) INHIBITOR
S24	0	S20 AND NS3 (W) INHIBITOR
S25	0	S20 AND NS3(W)INHIBITOR
S26	13	S20 AND NS3 AND INHIBITOR
S27	5	S26 AND HCV
S28	3	S20 AND NS3 AND NS4A AND PROTEASE AND INHIBITOR
S29	3	S28 AND HCV
S30	88	NS3 AND NS4A AND HCV AND PROTEASE AND INHIBITOR
S31	0	S30 AND METHODS AND PHARMACEUTICAL AND COMPOSITION AND COMPOUND AND PEPTIDE
S32	2	S30 AND PEPTIDE AND COMPOSITION
S33	57	S30 AND PEPTIDE
S34	3	S33 AND PHARMACEUTICAL

?

T S26/3,K/ALL
>>>KWIC option is not available in file(s): 399

26/3,K/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13216466 BIOSIS NO.: 200100423615
Peptide substrates for HCV NS3 protease assays.
AUTHOR: Zhang Rumin(a); Malcolm Bruce A; Beyer Brian M; Njoroge F George; Durkin James P; Windsor William T
AUTHOR ADDRESS: (a)Edison, NJ**USA
JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1247 (4):pNo Pagination June 26, 2001
MEDIUM: e-file
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

Peptide substrates for HCV NS3 protease assays.
...AUTHOR: Njoroge F George

ABSTRACT: Novel chromogenic, fluorogenic and fluorescence polarization substrates which are useful in HCV NS3 protease and inhibitor assays.
...REGISTRY NUMBERS: NS3 PROTEASE
DESCRIPTORS:
CHEMICALS & BIOCHEMICALS: NS3 protease...
METHODS & EQUIPMENT: hepatitis C virus NS3 protease assay...

26/3,K/2 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

11877258 EMBASE No: 2002449077
Establishment of a simple assay in vitro for hepatitis C virus NS3 serine protease based on recombinant substrate and single-chain protease
Du G.-X.; Hou L.-H.; Guan R.-B.; Tong Y.-G.; Wang H.-T.
Dr. G.-X. Du, Dept. of Applied Molecular Biology, Inst. of Microbiol. and Epidemiology, Fentai, Beijing 100071 China
AUTHOR EMAIL: dugx@hotmail.com
World Journal of Gastroenterology (WORLD J. GASTROENTEROL.) (China) 2002, 8/6 (1088-1093)
CODEN: WJGAF ISSN: 1007-9327
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 41

Establishment of a simple assay in vitro for hepatitis C virus NS3 serine protease based on recombinant substrate and single-chain protease
Du G.-X.; Hou L.-H.; Guan R.-B.; Tong Y.-G.; Wang H.-T.

Aim: To establish a simple and convenient assay in vitro for the Hepatitis C virus NS3 serine protease based on the recombinant protease and substrate, and to evaluate its feasibility in...
...in which the central sequence of cofactor NS4A was linked to the N-terminus of NS3 serine protease domain via a flexible linker GSGS. The fusion gene was obtained by two...

...EDTA had not. Conclusion: A simple and convenient assay in vitro for hepatitis C virus NS3 serine protease is based on recombinant substrate NS5ab and single-chain serine protase. This assay...
DRUG DESCRIPTORS:

*serine proteinase; *serine proteinase inhibitor --drug development--dv

26/3,K/3 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0291346 DBR Accession No.: 2002-13193 PATENT
Novel peptide inhibitor compounds of hepatitis virus NS3/NS4a serine protease, useful for treating hepatitis C virus disorders - protease-inhibitor peptide for virus infection therapy
AUTHOR: SAKSENA A K; GIRIJAVALLABHAN V M; LOVEY R G; JAO E E; BENNETT F ; MCCORMICK J; WANG H; PIKE R E; BOGEN S L; LIU Y; ARASAPPAN A; PAREKH T; PINTO P A; NJOROGE F G; GANGULY A K; BRUNCK T K; KEMP S J; LEVY O E; LIM-WILBY M
PATENT ASSIGNEE: SCHERING CORP; CORVAS INT INC 2002
PATENT NUMBER: WO 200208256 PATENT DATE: 20020131 WPI ACCESSION NO.: 2002-361644 (200239)
PRIORITY APPLIC. NO.: US 220109 APPLIC. DATE: 20000721
NATIONAL APPLIC. NO.: WO 2001US22826 APPLIC. DATE: 20010719
LANGUAGE: English

Novel peptide inhibitor compounds of hepatitis virus NS3 /NS4a serine protease, useful for treating hepatitis C virus disorders - protease-inhibitor peptide for virus infection therapy
AUTHOR: SAKSENA A K ; GIRIJAVALLABHAN V M ; LOVEY R G ; JAO E E ; BENNETT F ; MCCORMICK J ; WANG H ; PIKE R E ; BOGEN S L ; LIU Y ; ARASAPPAN A ; PAREKH T ; PINTO P A ; NJOROGE F G ; GANGULY A K ; BRUNCK T K ; KEMP S J ; LEVY O E ; LIM-WILBY M
...ABSTRACT: ACTIVITY - Virucide; hepatotrophic. No supporting data is given. MECHANISM OF ACTION - Hepatitis C virus (HCV) NS3 /NS4a serine protease inhibitors. USE - (I) is useful for manufacturing a medicament to treat disorders...

... I) having formula of (F2) is useful for modulating activity of HCV protease preferably, HCV NS3 /NS4a protease and for modulating the processing of HCV polypeptide. (II) is useful for treating...
DESCRIPTORS: hepatitis C virus NS3 , NS4a protease- inhibitor peptide prep., HPLC analysis, ribavirin, interferon-alpha virucide treatment, solid phase peptide synth., appl. hepatitis C virus infection therapy flavi virus enzyme- inhibitor chromatography protein sequence (21, 40)

26/3,K/4 (Item 2 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0291345 DBR Accession No.: 2002-13192 PATENT
Novel peptide compound having hepatitis C virus protease inhibitory activity useful for treating disorders associated with hepatitis C virus protease - protease-inhibitor peptide for virus infection therapy
AUTHOR: LIM-WILBY M; LEVY O E; BRUNCK T K
PATENT ASSIGNEE: CORVAS INT INC 2002
PATENT NUMBER: WO 200208251 PATENT DATE: 20020131 WPI ACCESSION NO.: 2002-361643 (200239)
PRIORITY APPLIC. NO.: US 220101 APPLIC. DATE: 20000721
NATIONAL APPLIC. NO.: WO 2001US23169 APPLIC. DATE: 20010719
LANGUAGE: English

...virus protease inhibitory activity useful for treating disorders associated with hepatitis C virus protease - protease- inhibitor peptide for virus infection therapy
AUTHOR: LIM-WILBY M ; LEVY O E ; BRUNCK T K
...ABSTRACT: antiviral agent (preferably ribavirin) and an interferon

(preferably alpha-interferon). ACTIVITY - Virucide. MECHANISM OF ACTION - Inhibitor of HCV NS3 /NS4a serine protease activity. The HCV protease inhibitory activity of (I) was examined using a... ... concentrations of enzyme and substrate. The results showed that the compounds had excellent utility as NS3 -serine protease inhibitors. USE - (I) is useful for treating and in the manufacture of a...
DESCRIPTORS: hepatitis C virus protease- inhibitor alpha-ketoamide peptide analog prep., HPLC, spectroscopy analysis, ribavirin, interferon-alpha virucide treatment, standard peptide synth., appl. hepatitis C virus infection therapy flavi virus enzyme- inhibitor chromatography protein sequence (21, 40)

26/3,K/5 (Item 3 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0290479 DBR Accession No.: 2002-12326 PATENT
Peptides are hepatitis C virus NS3-Serine protease inhibitor useful for treating disorders associated with Hepatitis C virus or HCV protease - enzyme-inhibitor, ribavarin and alpha-interferon treatment for infection therapy
AUTHOR: SAKSENA A K; GIRIJAVALLABHAN V M; BOGEN S L; LOVEY R G; JAO E E ; BENNETT F; MC CORMICK J L; WANG H; PIKE R E; LIU Y; CHAN T; ZHU Z; ARASAPPAN A; CHEN K X; VENKATRAMAN S; PAREKH T N; PINTO P A ; SANTHANAM B; NJOROGE F G; GANGULY A K; VACCARO H A; KEMP S J; LEVY O E; LIM-WILBY M; TAMURA S Y
PATENT ASSIGNEE: SCHERING CORP; CORVAS INT INC 2002
PATENT NUMBER: WO 200208187 PATENT DATE: 20020131 WPI ACCESSION NO.: 2002-280596 (200232)
PRIORITY APPLIC. NO.: US 220107 APPLIC. DATE: 20000721
NATIONAL APPLIC. NO.: WO 2001US22813 APPLIC. DATE: 20010719
LANGUAGE: English

Peptides are hepatitis C virus NS3 -Serine protease inhibitor useful for treating disorders associated with Hepatitis C virus or HCV protease - enzyme- inhibitor , ribavarin and alpha-interferon treatment for infection therapy
AUTHOR: SAKSENA A K ; GIRIJAVALLABHAN V M ; BOGEN S L ; LOVEY R G ; JAO E E ; BENNETT F ; MC CORMICK J L; WANG H ; PIKE R E ; LIU Y ; CHAN T; ZHU Z; ARASAPPAN A ; CHEN K X; VENKATRAMAN S; PAREKH T N ; PINTO P A ; SANTHANAM B; NJOROGE F G ; GANGULY A K ; VACCARO H A; KEMP S J ; LEVY O E ; LIM-WILBY M ; TAMURA S Y
...ABSTRACT: composition comprising (I) and a carrier. ACTIVITY - Antiviral; Hepatotropic. MECHANISM OF ACTION - Hepatitis C virus NS3 -Serine protease inhibitor . USE - (I) is used for the manufacture of a medicament or for treating disorders associated...
DESCRIPTORS: hepatitis C virus NS3 -serine protease- inhibitor , ribavarin, alpha-interferon treatment, appl. virucide, hepatitis C virus infection therapy flavi virus enzyme- inhibitor protein sequence (21, 38)

26/3,K/6 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

137047444 CA: 137(4)47444k PATENT
Preparation of diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus
INVENTOR(AUTHOR): Zhu, Zhaoning; Sun, Zhong-Yue; Venkatraman, Srikanth; Njoroge, F. George; Arasappan, Ashok; Malcolm, Bruce A.; Girijavallabhan, Viyyoor M.; Lovey, Raymond G.; Chen, Kevin X.
LOCATION: USA

ASSIGNEE: Schering Corporation
PATENT: PCT International ; WO 200248172 A2 DATE: 20020620
APPLICATION: WO 2001US47383 (20011210) *US PV254869 (20001212)
PAGES: 149 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; HR; HU; ID; IL; IN; IS; JP; KG; KR; KZ; LC; LK; LR; LT; LU; LV; MA; MD; MG; MK; MN; MX; MZ; NO; NZ; PH; PL; PT; RO; RU; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UZ; VN; YU; ZA; ZM; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

26/3,K/7 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

136167698 CA: 136(11)167698x PATENT
Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus
INVENTOR(AUTHOR): Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Lovey, Raymond G.; Jao, Edwin E.; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Chan, Tin-Yau; Liu, Yi-Tsung; Zhu, Zhaoning; Njoroge, F. George; Arasappan, Ashok; Parekh, Tejal N.; Ganguly, Ashit K.; Chen, Kevin X.; Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick A.; Santhanam, Bama; Wu, Wanli; Hendrata, Siska; Huang, Yuhua; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.
LOCATION: USA
ASSIGNEE: Schering Corporation; Corvas International, Inc.
PATENT: PCT International ; WO 200208244 A2 DATE: 20020131
APPLICATION: WO 2001US22678 (20010719) *US PV220108 (20000721)
PAGES: 536 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; HR; HU; ID; IL; IN; IS; JP; KG; KR; KZ; LC; LK; LR; LT; LU; LV; MA; MD; MG; MK; MN; MX; MZ; NO; NZ; PL; PT; RO; RU; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UZ; VN; YU; ZA; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

26/3,K/8 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

136151440 CA: 136(10)151440w PATENT
Preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus
INVENTOR(AUTHOR): Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Lovey, Raymond G.; Jao, Edwin E.; Bennett, Frank; McCormick, Jinping; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Liu, Yi-Tsung; Arasappan, Ashok; Parekh, Tejal; Pinto, Patrick A.; Njoroge, F. George; Ganguly, Ashit K.; Brunck, Terence K.; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita
LOCATION: USA
ASSIGNEE: Schering Corporation; Corvas International, Inc.
PATENT: PCT International ; WO 200208256 A2 DATE: 20020131
APPLICATION: WO 2001US22826 (20010719) *US PV220109 (20000721)
PAGES: 197 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-014/00A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; HR; HU;

ID; IL; IN; IS; JP; KG; KR; KZ; LC; LK; LR; LT; LU; LV; MA; MD; MG; MK; MN; MX; MZ; NO; NZ; PL; PT; RO; RU; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UZ; VN; YU; ZA; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH ; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

26/3,K/9 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

136151439 CA: 136(10)151439c PATENT

Preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus

INVENTOR(AUTHOR): Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Bogen, Stephane L.; Lovey, Raymond G.; Jao, Edwin E.; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Liu, Yi-Tsung; Chan, Tin-Yau; Zhu, Zhaoning; Arasappan, Ashok; Chen, Kevin X.; Venkatraman, Srikanth; Parekh, Tejal N.; Pinto, Patrick A.; Santhanam, Bama; Njoroge, F. George; Ganguly, Ashit K.; Vaccaro, Henry A.; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.

LOCATION: USA

ASSIGNEE: Schering Corporation; Corvas International, Inc.

PATENT: PCT International ; WO 200208187 A1 DATE: 20020131

APPLICATION: WO 2001US22813 (20010719) *US PV220107 (20000721)

PAGES: 188 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07D-209/02A; C07D-211/04B; C07D-233/56B; C07D-317/10B; C07D-319/04B; C07D-339/02B; C07D-339/08B; C07C-229/00B; C07C-233/05B; C07C-271/08B; C07C-271/32B; A61K-031/16B; A61K-031/27B; A61K-031/195B; A61K-031/357B; A61K-031/385B; A61K-031/403B; A61K-031/445B; A61K-031/4164B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; HR; HU; ID; IL; IN; IS; JP; KG; KR; KZ; LC; LK; LR; LT; LU; LV; MA; MD; MG; MK; MN; MX; MZ; NO; NZ; PL; PT; RO; RU; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UZ; VN; YU; ZA; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

26/3,K/10 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

136145200 CA: 136(10)145200b PATENT

Novel peptides as ns3-serine protease inhibitors of hepatitis C virus

INVENTOR(AUTHOR): Lim-Wilby, Marguerita; Levy, Odile E.; Brunck, Terrence K.

LOCATION: USA

ASSIGNEE: Corvas International, Inc.

PATENT: PCT International ; WO 200208251 A2 DATE: 20020131

APPLICATION: WO 2001US23169 (20010719) *US PV220101 (20000721)

PAGES: 69 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-007/00A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; HR; HU; ID; IL; IN; IS; JP; KG; KR; KZ; LC; LK; LR; LT; LU; LV; MA; MD; MG; MK; MN; MX; MZ; NO; NZ; PL; PT; RO; RU; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UZ; VN; YU; ZA; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH ; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

26/3,K/11 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

136135031 CA: 136(9)135031h PATENT
Preparation of novel imidazolidinones as NS3-serine protease inhibitors of hepatitis C virus
INVENTOR(AUTHOR): Arasappan, Ashok; Parekh, Tejal; Njoroge, F. George; Girijavallabhan, Viyyoor Moopil; Ganguily, Ashit K.
LOCATION: USA
ASSIGNEE: Schering Corporation
PATENT: PCT International ; WO 200208198 A2 DATE: 20020131
APPLICATION: WO 2001US22828 (20010719) *US PV220110 (20000721)
PAGES: 88 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07D-233/00A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; HR; HU; ID; IL; IN; IS; JP; KG; KR; KZ; LC; LK; LR; LT; LU; LV; MA; MD; MG; MK; MN; MX; MZ; NO; NZ; PL; PT; RO; RU; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UZ; VN; YU; ZA; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH ; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

26/3,K/12 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

135344735 CA: 135(24)344735j PATENT
Preparation of macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine p2 moieties
INVENTOR(AUTHOR): Venkatraman, Srikanth; Chen, Kevin X.; Arasappan, Ashok ; Njoroge, F. George; Girijavallabhan, Viyyoor M.; Chan, Tin-Yau; McKittrick, Brian A.; Prongay, Andrew J.; Madison, Vincent S.
LOCATION: USA
ASSIGNEE: Schering Corporation
PATENT: PCT International ; WO 200181325 A2 DATE: 20011101
APPLICATION: WO 2001US12530 (20010417) *US PV198204 (20000419)
PAGES: 218 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07D-273/00A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; HR; HU; ID; IL; IN; IS; JP; KG; KR; KZ; LC; LK; LR; LT; LU; LV; MA; MD; MG; MK; MN; MX; MZ; NO; NZ; PL; PT; RO; RU; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UZ; VN; YU; ZA; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM ; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

26/3,K/13 (Item 8 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

135318715 CA: 135(22)318715h PATENT
Preparation of macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising n-cyclic p2 moieties
INVENTOR(AUTHOR): Chen, Kevin X.; Arasappan, Ashok; Venkatraman, Srikanth ; Parekh, Tejal N.; Gu, Haining; Njoroge, F. George; Girijavallabhan, Viyyoor M.; Ganguly, Ashit; Saksena, Anil; Jao, Edwin; Yao, Nanhua H.; Prongay, Andrew J.; Madison, Vincent S.; Vibulbhan, Bancha
LOCATION: USA
ASSIGNEE: Schering Corporation
PATENT: PCT International ; WO 200177113 A2 DATE: 20011018
APPLICATION: WO 2001US10869 (20010403) *US PV194607 (20000405)

PAGES: 402 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07D-498/00A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; HR; HU; ID; IL; IN; IS; JP; KG; KR; KZ; LC; LK; LR; LT; LU; LV; MA; MD; MG; MK; MN; MX; MZ; NO; NZ; PL; PT; RO; RU; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UZ; VN; YU; ZA; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM ; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG
?

T S27/3,K/ALL
>>>KWIC option is not available in file(s): 399

27/3,K/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13216466 BIOSIS NO.: 200100423615
Peptide substrates for HCV NS3 protease assays.
AUTHOR: Zhang Rumin(a); Malcolm Bruce A; Beyer Brian M; Njoroge F George; Durkin James P; Windsor William T
AUTHOR ADDRESS: (a)Edison, NJ**USA
JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1247 (4):pNo Pagination June 26, 2001
MEDIUM: e-file
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

Peptide substrates for HCV NS3 protease assays.
...AUTHOR: Njoroge F George

ABSTRACT: Novel chromogenic, fluorogenic and fluorescence polarization substrates which are useful in HCV NS3 protease and inhibitor assays.
...REGISTRY NUMBERS: NS3 PROTEASE
DESCRIPTORS:
CHEMICALS & BIOCHEMICALS: NS3 protease...
METHODS & EQUIPMENT: hepatitis C virus NS3 protease assay...

27/3,K/2 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

11877258 EMBASE No: 2002449077
Establishment of a simple assay in vitro for hepatitis C virus NS3 serine protease based on recombinant substrate and single-chain protease
Du G.-X.; Hou L.-H.; Guan R.-B.; Tong Y.-G.; Wang H.-T.
Dr. G.-X. Du, Dept. of Applied Molecular Biology, Inst. of Microbiol. and Epidemiology, Fentai, Beijing 100071 China
AUTHOR EMAIL: dugx@hotmail.com
World Journal of Gastroenterology (WORLD J. GASTROENTEROL.) (China) 2002, 8/6 (1088-1093)
CODEN: WJGAF ISSN: 1007-9327
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 41

Establishment of a simple assay in vitro for hepatitis C virus NS3 serine protease based on recombinant substrate and single-chain protease
Du G.-X.; Hou L.-H.; Guan R.-B.; Tong Y.-G.; Wang H.-T.

Aim: To establish a simple and convenient assay in vitro for the Hepatitis C virus NS3 serine protease based on the recombinant protease and substrate, and to evaluate its feasibility in screening the enzyme inhibitors. Methods: Based on the crystallographic structure of hepatitis C virus (HCV) serine protease, a novel single-chain serine protease was designed, in which the central sequence of cofactor NS4A was linked to the N-terminus of NS3 serine protease domain via a flexible linker GSGS. The fusion gene was obtained by two...

...EDTA had not. Conclusion: A simple and convenient assay in vitro for

hepatitis C virus NS3 serine protease is based on recombinant substrate NS5ab and single-chain serine protase. This assay...
DRUG DESCRIPTORS:
*serine proteinase; *serine proteinase inhibitor --drug development--dv

27/3,K/3 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0291346 DBR Accession No.: 2002-13193 PATENT
Novel peptide inhibitor compounds of hepatitis virus NS3/NS4a serine protease, useful for treating hepatitis C virus disorders - protease-inhibitor peptide for virus infection therapy
AUTHOR: SAKSENA A K; GIRIJAVALLABHAN V M; LOVEY R G; JAO E E; BENNETT F ; MCCORMICK J; WANG H; PIKE R E; BOGEN S L; LIU Y; ARASAPPAN A; PAREKH T; PINTO P A; NJOROGE F G; GANGULY A K; BRUNCK T K; KEMP S J; LEVY O E; LIM-WILBY M
PATENT ASSIGNEE: SCHERING CORP; CORVAS INT INC 2002
PATENT NUMBER: WO 200208256 PATENT DATE: 20020131 WPI ACCESSION NO.: 2002-361644 (200239)
PRIORITY APPLIC. NO.: US 220109 APPLIC. DATE: 20000721
NATIONAL APPLIC. NO.: WO 2001US22826 APPLIC. DATE: 20010719
LANGUAGE: English

Novel peptide inhibitor compounds of hepatitis virus NS3 /NS4a serine protease, useful for treating hepatitis C virus disorders - protease-inhibitor peptide for virus infection therapy
AUTHOR: SAKSENA A K ; GIRIJAVALLABHAN V M ; LOVEY R G ; JAO E E ; BENNETT F ; MCCORMICK J ; WANG H ; PIKE R E ; BOGEN S L ; LIU Y ; ARASAPPAN A ; PAREKH T ; PINTO P A ; NJOROGE F G ; GANGULY A K ; BRUNCK T K ; KEMP S J ; LEVY O E ; LIM-WILBY M
ABSTRACT: DERWENT ABSTRACT: NOVELTY - A peptide compound (I) exhibiting hepatitis C virus (HCV) protease inhibitory activity, including enantiomers, stereoisomers, rotomers and tautomers, pharmaceutically acceptable salts, solvates or derivatives...

... which includes (S), is new. DETAILED DESCRIPTION - A peptide compound (I) exhibiting hepatitis C virus (HCV) protease inhibitory activity, including enantiomers, stereoisomers, rotomers and tautomers, pharmaceutically acceptable salts, solvates or derivatives...

...a formula of (F1) or (F2); and (2) preparing (II) for treating disorders associated with HCV protease involves bringing into intimate contact (I) of formula F1 or F2 and a carrier...

... interferon. ACTIVITY - Virucide; hepatotrophic. No supporting data is given. MECHANISM OF ACTION - Hepatitis C virus (HCV) NS3 /NS4a serine protease inhibitors. USE - (I) is useful for manufacturing a medicament to treat disorders associated with HCV protease. (I) having formula of (F2) is useful for modulating activity of HCV protease preferably, HCV NS3 /NS4a protease and for modulating the processing of HCV polypeptide. (II) is useful for treating disorders associated with hepatitis C virus and for treating disorders associated with HCV protease (all claimed). (I) is useful for treating hepatitis caused by HCV . ADMINISTRATION - (II) is administered by subcutaneous route. Dosages range from 1-252 mg (preferably 1...
DESCRIPTORS: hepatitis C virus NS3 , NS4a protease- inhibitor peptide prep., HPLC analysis, ribavirin, interferon-alpha virucide treatment, solid phase peptide synth., appl. hepatitis C virus infection therapy flavi virus enzyme- inhibitor chromatography protein sequence (21, 40)

27/3,K/4 (Item 2 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

0291345 DBR Accession No.: 2002-13192 PATENT
Novel peptide compound having hepatitis C virus protease inhibitory activity useful for treating disorders associated with hepatitis C virus protease - protease-inhibitor peptide for virus infection therapy
AUTHOR: LIM-WILBY M; LEVY O E; BRUNCK T K
PATENT ASSIGNEE: CORVAS INT INC 2002
PATENT NUMBER: WO 200208251 PATENT DATE: 20020131 WPI ACCESSION NO.: 2002-361643 (200239)
PRIORITY APPLIC. NO.: US 220101 APPLIC. DATE: 20000721
NATIONAL APPLIC. NO.: WO 2001US23169 APPLIC. DATE: 20010719
LANGUAGE: English

...**virus protease inhibitory activity useful for treating disorders associated with hepatitis C virus protease - protease- inhibitor peptide for virus infection therapy**
AUTHOR: LIM-WILBY M ; LEVY O E ; BRUNCK T K
ABSTRACT: DERWENT ABSTRACT: NOVELTY - Peptide compounds (I) containing 11 amino acid residues having hepatitis C virus (HCV) protease inhibitory activity, is new. (I) are alpha-ketoamide peptide analogs. DETAILED DESCRIPTION - New peptide compounds of formula (I) containing 11 amino acid residues having hepatitis C virus (HCV) protease inhibitory activity, including enantiomers, stereoisomers, rotomers and tautomers of the compound, and their salts...

... antiviral agent (preferably ribavirin) and an interferon (preferably alpha-interferon). ACTIVITY - Virucide. MECHANISM OF ACTION - Inhibitor of HCV NS3 /NS4a serine protease activity. The HCV protease inhibitory activity of (I) was examined using a spectrophotometry assay by following the procedures...

... concentrations of enzyme and substrate. The results showed that the compounds had excellent utility as NS3 -serine protease inhibitors. USE - (I) is useful for treating and in the manufacture of a medicament to treat disorders associated with HCV protease. (II) is useful for treating disorders associated with hepatitis C virus (claimed). ADMINISTRATION - Administration...

... 250) mg/day. EXAMPLE - A peptide compound, AcEEVVPnV-(CO)-GMSYS-Am having hepatitis C virus (HCV) protease inhibitory activity was synthesized. Initially, Fmoc-M-S(tBu)-Y(tBu)-S(tBu)-MBHA...
DESCRIPTORS: hepatitis C virus protease- inhibitor alpha-ketoamide peptide analog prep., HPLC, spectroscopy analysis, ribavirin, interferon-alpha virucide treatment, standard peptide synth., appl. hepatitis C virus infection therapy flavi virus enzyme- inhibitor chromatography protein sequence (21, 40)

27/3,K/5 (Item 3 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0290479 DBR Accession No.: 2002-12326 PATENT
Peptides are hepatitis C virus NS3-Serine protease inhibitor useful for treating disorders associated with Hepatitis C virus or HCV protease - enzyme-inhibitor, ribavarin and alpha-interferon treatment for infection therapy
AUTHOR: SAKSENA A K; GIRIJAVALLABHAN V M; BOGEN S L; LOVEY R G; JAO E E ; BENNETT F; MC CORMICK J L; WANG H; PIKE R E; LIU Y; CHAN T; ZHU Z; ARASAPPAN A; CHEN K X; VENKATRAMAN S; PAREKH T N; PINTO P A ; SANTHANAM B; NJOROGE F G; GANGULY A K; VACCARO H A; KEMP S J; LEVY O E; LIM-WILBY M; TAMURA S Y

PATENT ASSIGNEE: SCHERING CORP; CORVAS INT INC 2002
PATENT NUMBER: WO 200208187 PATENT DATE: 20020131 WPI ACCESSION NO.: 2002-280596 (200232)
PRIORITY APPLIC. NO.: US 220107 APPLIC. DATE: 20000721
NATIONAL APPLIC. NO.: WO 2001US22813 APPLIC. DATE: 20010719
LANGUAGE: English

Peptides are hepatitis C virus NS3 -Serine protease inhibitor useful for treating disorders associated with Hepatitis C virus or HCV protease - enzyme- inhibitor , ribavarin and alpha-interferon treatment for infection therapy

AUTHOR: SAKSENA A K ; GIRIJAVALLABHAN V M ; BOGEN S L ; LOVEY R G ; JAO E E ; BENNETT F ; MC CORMICK J L; WANG H ; PIKE R E ; LIU Y ; CHAN T; ZHU Z; ARASAPPAN A ; CHEN K X; VENKATRAMAN S; PAREKH T N ; PINTO P A ; SANTHANAM B; NJOROGE F G ; GANGULY A K ; VACCARO H A; KEMP S J ; LEVY O E ; LIM-WILBY M ; TAMURA S Y

...ABSTRACT: composition comprising (I) and a carrier. ACTIVITY - Antiviral; Hepatotropic. MECHANISM OF ACTION - Hepatitis C virus NS3 -Serine protease inhibitor . USE - (I) is used for the manufacture of a medicament or for treating disorders associated with Hepatitis C virus or HCV protease (all claimed). ADMINISTRATION - Administration is subcutaneous (claimed), oral or intravenous. Dosage is 1.0...

DESCRIPTORS: hepatitis C virus NS3 -serine protease- inhibitor , ribavarin, alpha-interferon treatment, appl. virucide, hepatitis C virus infection therapy flavi virus enzyme- inhibitor protein sequence (21, 38)

?

T S29/3,K/ALL
>>>KWIC option is not available in file(s): 399

29/3,K/1 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

11877258 EMBASE No: 2002449077
Establishment of a simple assay in vitro for hepatitis C virus NS3 serine protease based on recombinant substrate and single-chain protease
Du G.-X.; Hou L.-H.; Guan R.-B.; Tong Y.-G.; Wang H.-T.
Dr. G.-X. Du, Dept. of Applied Molecular Biology, Inst. of Microbiol. and Epidemiology, Fentai, Beijing 100071 China
AUTHOR EMAIL: dugx@hotmail.com
World Journal of Gastroenterology (WORLD J. GASTROENTEROL.) (China)
2002, 8/6 (1088-1093)
CODEN: WJGAF ISSN: 1007-9327
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 41

Establishment of a simple assay in vitro for hepatitis C virus NS3 serine protease based on recombinant substrate and single-chain protease
Du G.-X.; Hou L.-H.; Guan R.-B.; Tong Y.-G.; Wang H.-T.

Aim: To establish a simple and convenient assay in vitro for the Hepatitis C virus NS3 serine protease based on the recombinant protease and substrate, and to evaluate its feasibility in screening the enzyme inhibitors. Methods: Based on the crystallographic structure of hepatitis C virus (HCV) serine protease , a novel single-chain serine protease was designed, in which the central sequence of cofactor NS4A was linked to the N-terminus of NS3 serine protease domain via a flexible linker GSGS. The fusion gene was obtained by two-step PCR...

...vector pQE30, and the recombinant clone was verified by DNA sequencing. The single-chain recombinant protease was expressed when the E.coli was induced with IPTG and the expression conditions were optimized to produce large amont of soluble protease . The recombinant substrate NS5ab that covers the cleavage point NS5A/B was also expressed in E.coli. Both of the protease and substrate were purified by using Ni-NTA agarose metal affinity resin, then they were...

...The cleavage system was used to evaluate some compounds for their inhibitory activity on serine protease . Results: The single-chain recombinant protease was over-expressed as soluble protein when the E.coli was induced at a low dosage of IPTG (0.2 mM) and cultured at a low temperature (15 degreesC). The protease was purified by using Ni-NTA agarose metal affinity resin (the purity is over 95...

...simple and convenient assay in vitro was established, in which the purified single-chain serine protease could cleave the recombinant substrate NS5ab into two fragments that were visualized by SDS-PAGE, PMSF had an effect on inhibiting activity of serine protease , while EDTA had not. Conclusion: A simple and convenient assay in vitro for hepatitis C virus NS3 serine protease is based on recombinant substrate NS5ab and single-chain serine protase. This assay can be...
DRUG DESCRIPTORS:
*serine proteinase; *serine proteinase inhibitor --drug development--dv

29/3,K/2 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0291346 DBR Accession No.: 2002-13193 PATENT
Novel peptide inhibitor compounds of hepatitis virus NS3/NS4a serine protease, useful for treating hepatitis C virus disorders - protease-inhibitor peptide for virus infection therapy
AUTHOR: SAKSENA A K; GIRIJAVALLABHAN V M; LOVEY R G; JAO E E; BENNETT F ; MCCORMICK J; WANG H; PIKE R E; BOGEN S L; LIU Y; ARASAPPAN A; PAREKH T; PINTO P A; NJOROGE F G; GANGULY A K; BRUNCK T K; KEMP S J; LEVY O E; LIM-WILBY M
PATENT ASSIGNEE: SCHERING CORP; CORVAS INT INC 2002
PATENT NUMBER: WO 200208256 PATENT DATE: 20020131 WPI ACCESSION NO.: 2002-361644 (200239)
PRIORITY APPLIC. NO.: US 220109 APPLIC. DATE: 20000721
NATIONAL APPLIC. NO.: WO 2001US22826 APPLIC. DATE: 20010719
LANGUAGE: English

Novel peptide inhibitor compounds of hepatitis virus NS3 / NS4a serine protease , useful for treating hepatitis C virus disorders - protease - inhibitor peptide for virus infection therapy
AUTHOR: SAKSENA A K ; GIRIJAVALLABHAN V M ; LOVEY R G ; JAO E E ; BENNETT F ; MCCORMICK J ; WANG H ; PIKE R E ; BOGEN S L ; LIU Y ; ARASAPPAN A ; PAREKH T ; PINTO P A ; NJOROGE F G ; GANGULY A K ; BRUNCK T K ; KEMP S J ; LEVY O E ; LIM-WILBY M
ABSTRACT: DERWENT ABSTRACT: NOVELTY - A peptide compound (I) exhibiting hepatitis C virus (HCV) protease inhibitory activity, including enantiomers, stereoisomers, rotomers and tautomers, pharmaceutically acceptable salts, solvates or derivatives, of...

... which includes (S), is new. DETAILED DESCRIPTION - A peptide compound (I) exhibiting hepatitis C virus (HCV) protease inhibitory activity, including enantiomers, stereoisomers, rotomers and tautomers, pharmaceutically acceptable salts, solvates or derivatives, of...

...a formula of (F1) or (F2); and (2) preparing (II) for treating disorders associated with HCV protease involves bringing into intimate contact (I) of formula F1 or F2 and a carrier. BIOTECHNOLOGY...

... interferon. ACTIVITY - Virucide; hepatotrophic. No supporting data is given. MECHANISM OF ACTION - Hepatitis C virus (HCV) NS3 / NS4a serine protease inhibitors. USE - (I) is useful for manufacturing a medicament to treat disorders associated with HCV protease . (I) having formula of (F2) is useful for modulating activity of HCV protease preferably, HCV NS3 / NS4a protease and for modulating the processing of HCV polypeptide. (II) is useful for treating disorders associated with hepatitis C virus and for treating disorders associated with HCV protease (all claimed). (I) is useful for treating hepatitis caused by HCV . ADMINISTRATION - (II) is administered by subcutaneous route. Dosages range from 1-252 mg (preferably 1...
DESCRIPTORS: hepatitis C virus NS3 , NS4a protease - inhibitor peptide prep., HPLC analysis, ribavirin, interferon-alpha virucide treatment, solid phase peptide synth., appl. hepatitis C virus infection therapy flavi virus enzyme- inhibitor chromatography protein sequence (21, 40)

29/3,K/3 (Item 2 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0291345 DBR Accession No.: 2002-13192 PATENT
Novel peptide compound having hepatitis C virus protease inhibitory activity useful for treating disorders associated with hepatitis C virus protease - protease-inhibitor peptide for virus infection therapy
AUTHOR: LIM-WILBY M; LEVY O E; BRUNCK T K
PATENT ASSIGNEE: CORVAS INT INC 2002

PATENT NUMBER: WO 200208251 PATENT DATE: 20020131 WPI ACCESSION NO.: 2002-361643 (200239)
PRIORITY APPLIC. NO.: US 220101 APPLIC. DATE: 20000721
NATIONAL APPLIC. NO.: WO 2001US23169 APPLIC. DATE: 20010719
LANGUAGE: English

Novel peptide compound having hepatitis C virus protease inhibitory activity useful for treating disorders associated with hepatitis C virus protease - protease - inhibitor peptide for virus infection therapy

AUTHOR: LIM-WILBY M ; LEVY O E ; BRUNCK T K

ABSTRACT: DERWENT ABSTRACT: NOVELTY - Peptide compounds (I) containing 11 amino acid residues having hepatitis C virus (HCV) protease inhibitory activity, is new. (I) are alpha-ketoamide peptide analogs. DETAILED DESCRIPTION - New peptide compounds of formula (I) containing 11 amino acid residues having hepatitis C virus (HCV) protease inhibitory activity, including enantiomers, stereoisomers, rotomers and tautomers of the compound, and their salts, solvates...

... antiviral agent (preferably ribavirin) and an interferon (preferably alpha-interferon). ACTIVITY - Virucide. MECHANISM OF ACTION - Inhibitor of HCV NS3 / NS4a serine protease activity. The HCV protease inhibitory activity of (I) was examined using a spectrophotometry assay by following the procedures described...

... concentrations of enzyme and substrate. The results showed that the compounds had excellent utility as NS3 -serine protease inhibitors. USE - (I) is useful for treating and in the manufacture of a medicament to treat disorders associated with HCV protease . (II) is useful for treating disorders associated with hepatitis C virus (claimed). ADMINISTRATION - Administration is...

... 250) mg/day. EXAMPLE - A peptide compound, AcEEVVPnV-(CO)-GMSYS-Am having hepatitis C virus (HCV) protease inhibitory activity was synthesized. Initially, Fmoc-M-S(tBu)-Y(tBu)-S(tBu)-MBHA resin...

DESCRIPTORS: hepatitis C virus protease - inhibitor alpha-ketoamide peptide analog prep., HPLC, spectroscopy analysis, ribavirin, interferon-alpha virucide treatment, standard peptide synth., appl. hepatitis C virus infection therapy flavi virus enzyme- inhibitor chromatography protein sequence (21, 40)

?

T S34/3,K/ALL
>>>KWIC option is not available in file(s): 399

34/3,K/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11577771 BIOSIS NO.: 199800358467
Peptide-based inhibitors of the hepatitis C virus serine protease.
AUTHOR: Llinas-Brunet Montse(a); Bailey Murray; Fazal Gulrez; Goulet Sylvie ; Halmos Ted; Laplante Steven; Maurice Roger; Poirier Martin; Poupart Marc-Andre; Thibeault Diane; Wernic Dominik; Lamarre Daniel
AUTHOR ADDRESS: (a)Bio-Mega Res. Div., Boehringer Ingelheim (Canada) Ltd., 2100 Cunard, Laval, PQ H7S 2G5**Canada
JOURNAL: Bioorganic & Medicinal Chemistry Letters 8 (13):p1713-1718 July 7, 1998
ISSN: 0960-894X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

Peptide -based inhibitors of the hepatitis C virus serine protease .

ABSTRACT: Hexapeptide DDIVPC-OH is a competitive inhibitor of the hepatitis C virus (HCV) NS3 protease complexed with NS4A cofactor peptide . This hexapeptide corresponds to the N-terminal cleavage product of an HCV dodecapeptide substrate derived from the NS5A/5B cleavage site. Structure-activity studies on Ac-DDIVPC...
...REGISTRY NUMBERS: SERINE PROTEASE ; ...

... PROTEASE
DESCRIPTORS:
CHEMICALS & BIOCHEMICALS: ... peptide drugs...

...serine protease --...

...enzyme inhibitor , synthesis, pharmaceutical ; NS3 ...

...NS3 protease--...

... NS4A cofactor peptide

34/3,K/2 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0291346 DBR Accession No.: 2002-13193 PATENT
Novel peptide inhibitor compounds of hepatitis virus NS3/NS4a serine protease, useful for treating hepatitis C virus disorders - protease-inhibitor peptide for virus infection therapy
AUTHOR: SAKSENA A K; GIRIJAVALLABHAN V M; LOVEY R G; JAO E E; BENNETT F ; MCCORMICK J; WANG H; PIKE R E; BOGEN S L; LIU Y; ARASAPPAN A; PAREKH T; PINTO P A; NJOROGE F G; GANGULY A K; BRUNCK T K; KEMP S J; LEVY O E; LIM-WILBY M
PATENT ASSIGNEE: SCHERING CORP; CORVAS INT INC 2002
PATENT NUMBER: WO 200208256 PATENT DATE: 20020131 WPI ACCESSION NO.: 2002-361644 (200239)
PRIORITY APPLIC. NO.: US 220109 APPLIC. DATE: 20000721
NATIONAL APPLIC. NO.: WO 2001US22826 APPLIC. DATE: 20010719
LANGUAGE: English

Novel peptide inhibitor compounds of hepatitis virus NS3 / NS4a serine protease , useful for treating hepatitis C virus disorders -

protease - inhibitor peptide for virus infection therapy

ABSTRACT: DERWENT ABSTRACT: NOVELTY - A peptide compound (I) exhibiting hepatitis C virus (HCV) protease inhibitory activity, including enantiomers, stereoisomers, rotomers and tautomers, pharmaceutically acceptable salts, solvates or derivatives, of a general formula (F1) or (F2) which includes (S), is new. DETAILED DESCRIPTION - A peptide compound (I) exhibiting hepatitis C virus (HCV) protease inhibitory activity, including enantiomers, stereoisomers, rotomers and tautomers, pharmaceutically acceptable salts, solvates or derivatives, of...

... part of the cyclic ring. INDEPENDENT CLAIMS are also included for the following: (1) a pharmaceutical composition (II) comprising a formula of (F1) or (F2); and (2) preparing (II) for treating disorders associated with HCV protease involves bringing into intimate contact (I) of formula F1 or F2 and a carrier. BIOTECHNOLOGY - Preferred Pharmaceutical Composition: Pharmaceutical composition comprising (I) having a formula of (F1) additionally comprises an antiviral agent and an...

... interferon. ACTIVITY - Virucide; hepatotrophic. No supporting data is given. MECHANISM OF ACTION - Hepatitis C virus (HCV) NS3 / NS4a serine protease inhibitors. USE - (I) is useful for manufacturing a medicament to treat disorders associated with HCV protease . (I) having formula of (F2) is useful for modulating activity of HCV protease preferably, HCV NS3 / NS4a protease and for modulating the processing of HCV polypeptide . (II) is useful for treating disorders associated with hepatitis C virus and for treating disorders associated with HCV protease (all claimed). (I) is useful for treating hepatitis caused by HCV . ADMINISTRATION - (II) is administered by subcutaneous route. Dosages range from 1-252 mg (preferably 1...

DESCRIPTORS: hepatitis C virus NS3 , NS4a protease - inhibitor peptide prep., HPLC analysis, ribavirin, interferon-alpha virucide treatment, solid phase peptide synth., appl. hepatitis C virus infection therapy flavi virus enzyme- inhibitor chromatography protein sequence (21, 40)

34/3,K/3 (Item 2 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

0291345 DBR Accession No.: 2002-13192 PATENT

Novel peptide compound having hepatitis C virus protease inhibitory activity useful for treating disorders associated with hepatitis C virus protease - protease-inhibitor peptide for virus infection therapy

AUTHOR: LIM-WILBY M; LEVY O E; BRUNCK T K
PATENT ASSIGNEE: CORVAS INT INC 2002
PATENT NUMBER: WO 200208251 PATENT DATE: 20020131 WPI ACCESSION NO.: 2002-361643 (200239)
PRIORITY APPLIC. NO.: US 220101 APPLIC. DATE: 20000721
NATIONAL APPLIC. NO.: WO 2001US23169 APPLIC. DATE: 20010719
LANGUAGE: English

Novel peptide compound having hepatitis C virus protease inhibitory activity useful for treating disorders associated with hepatitis C virus protease - protease - inhibitor peptide for virus infection therapy

ABSTRACT: DERWENT ABSTRACT: NOVELTY - Peptide compounds (I) containing 11 amino acid residues having hepatitis C virus (HCV) protease inhibitory activity, is new. (I) are alpha-ketoamide peptide analogs. DETAILED DESCRIPTION - New peptide compounds of formula (I) containing 11 amino acid residues having hepatitis C virus (HCV)

protease inhibitory activity, including enantiomers, stereoisomers, rotomers and tautomers of the compound, and their salts, solvates or derivatives, are new. (I) are alpha-ketoamide peptide analogs. X = COCH(R4)NHCOCH(R5)NHCOCH(R6)NHCORn, or COCH(R4)NHCOCH(R5)NHCOCH...

... optionally substituted with Q1); andm = 0-2; An INDEPENDENT CLAIM is also included for a pharmaceutical composition (II) comprising (I) as an active ingredient. BIOTECHNOLOGY - Preferred Composition: (II) additionally comprises an antiviral agent (preferably ribavirin) and an interferon (preferably alpha-interferon). ACTIVITY - Virucide. MECHANISM OF ACTION - Inhibitor of HCV NS3 / NS4a serine protease activity. The HCV protease inhibitory activity of (I) was examined using a spectrophotometry assay by following the procedures described...

... concentrations of enzyme and substrate. The results showed that the compounds had excellent utility as NS3 -serine protease inhibitors. USE - (I) is useful for treating and in the manufacture of a medicament to treat disorders associated with HCV protease . (II) is useful for treating disorders associated with hepatitis C virus (claimed). ADMINISTRATION - Administration is...

... claimed), orally or intravenously. Dosage is 1-1000 (preferably 1-250) mg/day. EXAMPLE - A peptide compound, AcEEVVPnV-(CO)-GMSYS-Am having hepatitis C virus (HCV) protease inhibitory activity was synthesized. Initially, Fmoc-M-S(tBu)-Y(tBu)-S(tBu)-MBHA resin...

DESCRIPTORS: hepatitis C virus protease - inhibitor alpha-ketoamide peptide analog prep., HPLC, spectroscopy analysis, ribavirin, interferon-alpha virucide treatment, standard peptide synth., appl. hepatitis C virus infection therapy flavi virus enzyme- inhibitor chromatography protein sequence (21, 40)

?

L Number	Hits	Search Text	DB	Time stamp
1	3151	"hepatitis C virus"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:37
7	1333	"hepatitis C virus".ab.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:37
13	970	"hepatitis C virus".ti.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:38
19	1483	HCV.ab.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:38
25	134	"HCV protease"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:39
31	52	"HCV protease".ab.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:39
37	121	"HCV protease" and inhibitor	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:39
43	32	"HCV protease".ab. and inhibitor.ab.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:40
49	6	"HCV inhibitor".ab.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:40
55	36	"NS3/NS4a"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:44
61	0	"NS-3/NS4a"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:44
67	11	"NS3/NS4a".ab.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:46
73	172	"HCV polypeptide"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:45
85	93	"HCV peptide"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:45
91	276	"HCV protein"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:45
97	10	"NS3/NS4a".ab. and inhibitor.ab.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:08
103	0	"NS3/NS4a".ab. and inhibitor.ab. and 435/6.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:08

109	0	"NS3/NS4a".ab. and inhibitor.ab. and 435/5.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:09
121	0	"NS3/NS4a".ab. and 435/5.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:09
115	9	"NS3/NS4a" and 435/5.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:09
127	0	"NS3/NS4a".ab. and 435/6.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:09
133	0	"NS3/NS4a".ab. and 435/23.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:09
139	6	"NS3 protease" and inhibitor and 514/18.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:10
145	22	"NS3 protease" and inhibitor and 435/6.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:10
151	0	"NS3 protease".ab. and inhibitor.ab. and 435/6.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:10
157	2	"NS3 protease".ab. and inhibitor.ab. and 435/5.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:10
169	0	"NS3 protease".ab. and inhibitor.ab. and 435/6.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:11
181	0	"NS3 protease".ab. and inhibitor.ab. and 514/18.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:11
187	0	"NS3 protease".ab. and inhibitor.ab. and 514/16.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:11
193	0	"NS3 protease".ab. and inhibitor.ab. and 514/9.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:11
199	0	"NS3 protease".ab. and inhibitor.ab. and 514/160.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:11
205	0	"NS3 protease".ab. and inhibitor.ab. and 424/85.4.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:11
211	1	"NS3 protease".ab. and inhibitor.ab. and 530/324.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:12
217	0	"NS3 protease".ab. and inhibitor.ab. and 530/325.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:12

223	2	"NS3 protease".ab. and inhibitor.ab. and 530/326.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:13
241	2	"NS3 protease".ab. and inhibitor.ab. and 530/329.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:13
247	2	"NS3 protease".ab. and inhibitor.ab. and 530/332.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:13
229	2	"NS3 protease".ab. and inhibitor.ab. and 530/327.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:14
235	1	"NS3 protease".ab. and inhibitor.ab. and 530/328.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:14
175	2	"NS3 protease".ab. and inhibitor.ab. and 435/23.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:14
163	3	"NS3 protease".ab. and inhibitor and 435/5.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:15
-	2	6251583.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/19 05:54
-	2	6265380.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/19 08:55
-	2	5990276.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/19 09:28
-	2	9718968.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/19 09:28
-	2	9718968.did.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/19 09:28
-	2	9817679.did.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:36

=> d ibib abs hitstr l13 16

L13 ANSWER 16 OF 17 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:268513 HCAPLUS
DOCUMENT NUMBER: 128:321945
TITLE: Preparation of peptide analogs as inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
INVENTOR(S): Tung, Roger D.; Harbeson, Scott L.; Deininger, David D.; Murcko, Mark A.; Bhisetti, Govinda Rao; Farmer, Luc J.
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Inc., USA; Tung, Roger D.; Harbeson, Scott L.; Deininger, David D.; Murcko, Mark A.; Bhisetti, Govinda Rao; Farmer, Luc J.
SOURCE: PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817679	A1	19980430	WO 1997-US18968	19971017
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9709327	A	19980511	ZA 1997-9327	19971017
AU 9851477	A1	19980515	AU 1998-51477	19971017
AU 719984	B2	20000518		
EP 932617	A1	19990804	EP 1997-946273	19971017
EP 932617	B1	20020116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9712544	A	19991019	BR 1997-12544	19971017
CN 1238780	A	19991215	CN 1997-180151	19971017
NZ 335276	A	20000929	NZ 1997-335276	19971017
JP 2001502694	T2	20010227	JP 1998-519568	19971017
EP 1136498	A1	20010926	EP 2001-109433	19971017
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AP 1019	A	20011016	AP 1999-1512	19971017
W: GH, KE, LS, MW, SD, SZ, UG, ZW				
AT 212037	E	20020215	AT 1997-946273	19971017
ES 2169880	T3	20020716	ES 1997-946273	19971017
NO 9901832	A	19990617	NO 1999-1832	19990416
US 6265380	B1	20010724	US 1999-293247	19990416
KR 2000049263	A	20000725	KR 1999-703372	19990417
US 2002032175	A1	20020314	US 2001-875390	20010606

PRIORITY APPLN. INFO.:
US 1996-28290P P 19961018
EP 1997-946273 A3 19971017
WO 1997-US18968 W 19971017
US 1999-293247 A 19990416

OTHER SOURCE(S): MARPAT 128:321945
GI



I



II



III

AB The present invention relates to compds. I [G1 = SH, OH, SMe, alkenyl, alkynyl, CF3, C1-2 alkoxy, C1-2 alkylthio, (un)substituted C1-3 alkyl; W1 = COCF2CH2N(G4)U, CHO, COG2, COCF2CF3, COCOG2, COCO2G2, B(Q1)2; G2 = alkyl, aryl, aralkyl, (un)substituted mono-, bi-, or tricyclic heterocycle; G4 = alky, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, aryl, aralkyl, aralkenyl, etc.; Q1 = OH, alkoxy, aryloxy, or Q1-Q1 form a 5-7 membered ring; U = H, G9CO, G9SO2, G9COCO, (G9)2NCOCO, (G9)2NSO2, (G9)2NCO, G9O2C; G9 = H, alkyl, carboxyalkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, heterocycloalkyl, etc; or G9-G9 form a ring; E4 = bond, .alpha.-amino acid residue, heterocyclic amino acid; E5-E8 = independently bond, amino acid residue; 1-2 peptide bonds between E5-E8 may be reduced], methods and pharmaceutical compns. for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compds., and the compns. and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus. Thus, peptide aldehyde II was prepd. using solid-phase methods on a benzhydrylamine resin and tert-butoxycarbonyl (Boc) and 9-fluorenylmethoxycarbonyl (Fmoc) protection starting from protected hydrazone III. Nearly 200 compds. I were prepd. and tested for hepatitis C virus NS3 protease inhibitory activity, with II exhibiting Ki <1 .mu.M in an in vitro assay.

IT **207001-61-4P 207001-82-9P 207001-83-0P**
207001-84-1P 207001-85-2P 207001-86-3P
207001-87-4P 207001-88-5P 207001-89-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT

(Reactant or reagent); USES (Uses)
(prepn. of peptide analogs as hepatitis C virus NS3 protease inhibitors)

RN **207001-88-5** REGISTRY
CN L-Leucinamide, N-acetyl-L-α-glutamyl-L-α-aspartyl-L-valyl-L-valyl-N-[(1S)-1-ethyl-2,3-dioxo-3-[(4-pyridinylmethyl)amino]propyl]- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C38 H58 N8 O12
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)